Impact BioMedical Inc. (IBO) operates as a Houston-based biotech holding company with roughly two full-time employees and trailing-twelve-month revenue around $38,000. Its early-stage profile means mainstream analysts do not issue price targets, and standard data sources show no coverage or consensus. The $10.50 figure therefore stems from public references to the stock's 52-week high, which ranged between about $10.47 and $10.51 and rounds to $10.50. This marks a prior peak and technical resistance area, not a valuation-driven projection. It poses the question of whether the shares could revisit that recent high rather than predicting an outcome.
The stock closed near $5.14 in mid-November 2026, well below its 52-week high of roughly $10.51 yet above the low of about $2.43. Closing the gap to $10.50 would require a gain of approximately 104%, a sizable advance for any equity and particularly one with a beta near 2.9 that trades on limited volume. Progress would likely hinge more on event catalysts than near-term fundamentals, given negligible revenue and continued losses. A completed merger with Zoar Ltd. might reshape the capital structure, while licensing advances on the Linebacker platform, already licensed to ProPhase Laboratories for oncology uses, could influence sentiment. Without those drivers, any move would depend mainly on technical momentum.
The pending combination with Zoar Ltd. stands out as the primary potential catalyst, especially following the 1-for-12.62 reverse split executed to support exchange compliance. Successful completion could change share count, liquidity, and strategic focus. The company's patent holdings cover oncology, anti-inflammatory, antiviral, and wellness applications, including Linebacker, Laetose, Equivir, and 3F platforms, any of which might lead to licensing or royalty deals. The reverse split helps preserve listing status, and trading above the 50-day moving average recently indicates short-term technical support.
Challenges remain significant. Revenue of around $38,000 is negligible, and the company posted a net loss of approximately $11.87 million for fiscal 2025, with cash at about $21,000 and negative operating cash flow. Operations rely on financing, licensing revenue, or the merger outcome, and additional share issuance would dilute holders. Governance risks include multiple prior reverse splits, such as the 1-for-55 action in 2023, plus majority ownership by DSS BioHealth Security. Institutional ownership stays low, the float is limited, and volatility is extreme, so sustained interest needed for a retest of $10.50 is not assured.
The $10.50 zone represents the main resistance at the 52-week high. Intermediate markers include the 200-day moving average near $6.18 and the 50-day moving average around $4.88. Support levels feature the October 2026 swing low near $2.68 and the 52-week low of about $2.43. To make $10.50 attainable, the stock would likely need to reclaim and hold the 200-day average first.
With no formal 12-month analyst target, the $10.50 level lacks a defined research horizon. Focus should remain on the Zoar Ltd. merger status and terms, any resulting share-count adjustments, licensing or royalty updates, quarterly cash positions and losses, and exchange compliance notices. Regulatory developments around the therapeutic platforms and overall market appetite for speculative biotech names also matter. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
The $10.50 reference is a technical milestone tied to the 52-week high rather than an analyst-derived valuation. From the recent price near $5.14, it would demand a move of roughly 104%. Support rests primarily on catalysts such as the Zoar Ltd. merger and IP progress, against a backdrop of minimal revenue, recurring losses, thin cash, and repeated reverse splits. No credible consensus exists, and the outcome remains highly uncertain. Investors should treat the level as a reference to watch against news flow rather than a guaranteed destination.
In my own workflow, Tickeron's AI Daily Buy/Sell Signals provide a practical way to track momentum shifts across volatile names like this one. The system applies artificial intelligence to scan thousands of stocks and ETFs, producing Buy, Sell, or Hold signals based on evolving market conditions and technical patterns. For a development-stage biotech with thin trading, these signals help surface potential changes in trend or momentum without replacing broader due diligence. I find them useful for refining entry and exit ideas alongside other analysis, though they serve best as one input among several.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
My name is Jimmy, and I’m a financial analyst focused on identifying compelling opportunities across the ETF market. Each day, I analyze hundreds of ETFs to uncover potential trading and investment opportunities using a broad range of market factors. For short-term trading, I rely heavily on technical analysis, including price channels, momentum indicators, support and resistance levels, trend patterns, and other market signals. At the same time, I dedicate significant attention to evaluating ETFs from a long-term investment perspective. My objective is to build a well-balanced ETF portfolio that combines core investment holdings with more tactical and speculative positions. The goal is to create a portfolio that can participate effectively in market rallies while also remaining resilient during periods of volatility and market corrections.
The RSI Indicator for IBO moved out of oversold territory on October 20, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 9 similar instances when the indicator left oversold territory. In 8 of the 9 cases the stock moved higher. This puts the odds of a move higher at 89%.
The Momentum Indicator moved above the 0 level on October 28, 2026. You may want to consider a long position or call options on IBO as a result. In 32 of 41 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 78%.
The Moving Average Convergence Divergence (MACD) for IBO just turned positive on October 23, 2026. Looking at past instances where IBO's MACD turned positive, the stock continued to rise in 13 of 15 cases over the following month. The odds of a continued upward trend are 87%.
IBO moved above its 50-day moving average on November 13, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +19.54% 3-day Advance, the price is estimated to grow further. Considering data from situations where IBO advanced for three days, in 72 of 91 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
The Aroon Indicator entered an Uptrend today. In 28 of 32 cases where IBO Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 88%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 7 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IBO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
IBO broke above its upper Bollinger Band on November 13, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron SMR rating for this company is 8 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of 30 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 42 (best 1 - 100 worst), indicating steady price growth. IBO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 78 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 82 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.254) is normal, around the industry mean (3.586). P/E Ratio (0.369) is within average values for comparable stocks, (-1.188). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (1111.111) is also within normal values, averaging (440.869).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IBO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry Biotechnology